Despite the uncertainties, some authors advocated—long before the release of the promising adjuvant trastuzumab data—that, because of its prognostic usefulness, HER2 testing be routinely performed for all new breast cancer cases 13. This evidence concerns the gene ERBB2 and breast cancer.